Endurance Wealth Management Stake in Amgen (AMGN) Has Lowered by $621,000 as Valuation Declined; Amgen Com (AMGN) Market Valuation Declined While Palladium Partners Has Cut by $434,907 Its Holding

Amgen Inc. (NASDAQ:AMGN) Logo

Palladium Partners Llc decreased its stake in Amgen Inc Com (AMGN) by 2.56% based on its latest 2018Q3 regulatory filing with the SEC. Palladium Partners Llc sold 2,101 shares as the company’s stock declined 4.15% with the market. The institutional investor held 79,990 shares of the biological products (no diagnostic substances) company at the end of 2018Q3, valued at $16.58 million, down from 82,091 at the end of the previous reported quarter. Palladium Partners Llc who had been investing in Amgen Inc Com for a number of months, seems to be less bullish one the $128.66B market cap company. The stock increased 0.76% or $1.53 during the last trading session, reaching $201.9. About 607,278 shares traded. Amgen Inc. (NASDAQ:AMGN) has risen 11.57% since January 10, 2018 and is uptrending. It has outperformed by 11.57% the S&P500. Some Historical AMGN News: 29/03/2018 – FDA Approves BLINCYTO(R) (blinatumomab) to Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia in Adults and Children; 17/04/2018 – Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig™ (erenumab) For Migraine Patients With Multiple Treatment Failures; 08/03/2018 – AMGEN REPORTS FINAL RESULTS OF TENDER OFFER; 24/04/2018 – AMGEN INC AMGN.O FY2018 SHR VIEW $13.48, REV VIEW $22.61 BLN — THOMSON REUTERS l/B/E/S; 19/03/2018 – Mersana Strengthens Bd of Directors Leadership With Appointment of Willard H. Dere, M.D., Professor at the University of Utah and Retired Chief Medical Officer of Amgen; 11/04/2018 – Amgen Inc. | human immunoglobulin (IgG1K) monoclonal antibody that binds to interleukin 15 | N/A | 04/10/2018 | Treatment of refractory celiac disease. | Designated | NFDA | N/A | | N/A; 10/03/2018 – REGENERON, SANOFI’S PRALUENT CUTS HEART RISKS BY 15% IN STUDY; 17/04/2018 – New — Blockbuster ambitions: Amgen/Novartis team lines up more promising PhIII erenumab data for some of the toughest migraine patients $AMGN $NVS $LLY; 06/03/2018 – Amgen Preliminary Proration Factor for Tender Offer Is Approximately 95.9%; 03/04/2018 – European Commission Approves Expanded lndication For Amgen’s XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma

Endurance Wealth Management Inc decreased its stake in Amgen Inc (AMGN) by 8.84% based on its latest 2018Q3 regulatory filing with the SEC. Endurance Wealth Management Inc sold 3,000 shares as the company’s stock declined 4.15% with the market. The institutional investor held 30,926 shares of the biological products (no diagnostic substances) company at the end of 2018Q3, valued at $6.41M, down from 33,926 at the end of the previous reported quarter. Endurance Wealth Management Inc who had been investing in Amgen Inc for a number of months, seems to be less bullish one the $128.66 billion market cap company. The stock increased 0.76% or $1.53 during the last trading session, reaching $201.9. About 607,278 shares traded. Amgen Inc. (NASDAQ:AMGN) has risen 11.57% since January 10, 2018 and is uptrending. It has outperformed by 11.57% the S&P500. Some Historical AMGN News: 05/04/2018 – AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes With Samsung Bioepis; 16/05/2018 – Amgen Receives European Commission Approval for Repatha(R) (Evolocumab) to Prevent Heart Attack and Stroke in Adults With Established Cardiovascular Disease; 24/04/2018 – Amgen posts higher 1st-quarter profit as sales rise 3 percent; 08/05/2018 – LUPIN LTD LUPN.NS SAYS SUBMITS NEW DRUG APPLICATION FOR ETANERCEPT BIOSIMILAR IN JAPAN; 17/05/2018 – NOVARTIS AND AMGEN ANNOUNCE FDA APPROVAL OF AIMOVIG™ (ERENUMAB-AOOE), A NOVEL TREATMENT DEVELOPED SPECIFICALLY FOR MIGRAINE PREVENTION; 17/05/2018 – Novartis and Amgen announce FDA approval of Aimovig™ (erenumab-aooe), a novel treatment developed specifically for migraine p; 24/04/2018 – FOCUS-Express Scripts targets Amgen, Lilly migraine drugs in pricing shift; 23/03/2018 – AMGEN CONFIRMS POSITIVE CHMP OPINION RECOGNIZING REPATHA; 25/05/2018 – Amgen Granted FDA Orphan Drug Status for Romiplostim; 17/05/2018 – U.S. FDA SAYS IT THE APPROVAL OF AIMOVIG TO AMGEN INC

More notable recent Amgen Inc. (NASDAQ:AMGN) news were published by: Nasdaq.com which released: “Health Care Sector Update for 01/10/2019: PRPO,CGIX, PHG, JNJ, PFE, MRK, ABT, AMGN – Nasdaq” on January 10, 2019, also Nasdaq.com with their article: “Amgen (AMGN) Stock Moves -1.52%: What You Should Know – Nasdaq” published on January 03, 2019, Nasdaq.com published: “Health Care Sector Update for 01/07/2019: LOXO, LLY, MYND, AXSM, JNJ, PFE, MRK, ABT, AMGN – Nasdaq” on January 07, 2019. More interesting news about Amgen Inc. (NASDAQ:AMGN) were released by: Nasdaq.com and their article: “Health Care Sector Update for 12/11/2018: ENTX, AMGN, ITCI, NVS, JNJ, PFE, MRK, ABT – Nasdaq” published on December 11, 2018 as well as Nasdaq.com‘s news article titled: “Health Care Sector Update for 12/31/2018: VTVT, ADMP, MBOT, JNJ, PFE, MRK, ABT, AMGN – Nasdaq” with publication date: December 31, 2018.

Investors sentiment decreased to 0.87 in 2018 Q3. Its down 0.12, from 0.99 in 2018Q2. It turned negative, as 49 investors sold AMGN shares while 550 reduced holdings. 130 funds opened positions while 393 raised stakes. 470.42 million shares or 2.68% less from 483.36 million shares in 2018Q2 were reported. Mechanics National Bank & Trust Department has invested 0.16% in Amgen Inc. (NASDAQ:AMGN). First City Cap Management Inc accumulated 3,820 shares. Old Point Trust & Services N A reported 2.48% stake. Tdam Usa accumulated 12,803 shares. Ubs Asset Mgmt Americas reported 0% in Amgen Inc. (NASDAQ:AMGN). Zurcher Kantonalbank (Zurich Cantonalbank) holds 0.36% in Amgen Inc. (NASDAQ:AMGN) or 205,853 shares. Nuveen Asset Ltd Llc has 365,157 shares. Yorktown Mgmt & Com stated it has 0.41% of its portfolio in Amgen Inc. (NASDAQ:AMGN). Amica Pension Fund Board Of Trustees reported 0.52% stake. Mraz Amerine & Inc stated it has 0.37% in Amgen Inc. (NASDAQ:AMGN). Texas-based King Luther has invested 0.95% in Amgen Inc. (NASDAQ:AMGN). State Street Corporation reported 27.04 million shares stake. Cypress Group invested in 0.71% or 18,096 shares. Clear Harbor Asset Mgmt Llc holds 0.26% or 6,803 shares in its portfolio. First Manhattan Company has invested 0.34% in Amgen Inc. (NASDAQ:AMGN).

Since November 29, 2018, it had 0 insider purchases, and 2 selling transactions for $4.27 million activity. Jacks Tyler sold 20,000 shares worth $3.91 million.

Among 27 analysts covering Amgen Inc. (NASDAQ:AMGN), 11 have Buy rating, 0 Sell and 16 Hold. Therefore 41% are positive. Amgen Inc. had 101 analyst reports since August 3, 2015 according to SRatingsIntel. Piper Jaffray maintained Amgen Inc. (NASDAQ:AMGN) rating on Thursday, February 1. Piper Jaffray has “Buy” rating and $190.0 target. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, July 31 report. The firm earned “Buy” rating on Wednesday, July 12 by Oppenheimer. Jefferies maintained Amgen Inc. (NASDAQ:AMGN) on Monday, June 12 with “Hold” rating. On Friday, February 2 the stock rating was maintained by BMO Capital Markets with “Market Perform”. Morgan Stanley maintained it with “Overweight” rating and $196 target in Friday, February 2 report. The company was maintained on Monday, January 22 by RBC Capital Markets. The rating was initiated by Gabelli on Friday, August 26 with “Hold”. The firm earned “Overweight” rating on Friday, February 2 by PiperJaffray. The stock of Amgen Inc. (NASDAQ:AMGN) has “Buy” rating given on Tuesday, November 8 by Mizuho.

Endurance Wealth Management Inc, which manages about $847.31M and $635.61M US Long portfolio, upped its stake in Ipg Photonics Corp Com (NASDAQ:IPGP) by 2,805 shares to 2,985 shares, valued at $465,000 in 2018Q3, according to the filing.

Analysts await Amgen Inc. (NASDAQ:AMGN) to report earnings on February, 7. They expect $3.25 EPS, up 12.46% or $0.36 from last year’s $2.89 per share. AMGN’s profit will be $2.07 billion for 15.53 P/E if the $3.25 EPS becomes a reality. After $3.69 actual EPS reported by Amgen Inc. for the previous quarter, Wall Street now forecasts -11.92% negative EPS growth.

Analysts await Amgen Inc. (NASDAQ:AMGN) to report earnings on February, 7. They expect $3.25 EPS, up 12.46% or $0.36 from last year’s $2.89 per share. AMGN’s profit will be $2.07B for 15.53 P/E if the $3.25 EPS becomes a reality. After $3.69 actual EPS reported by Amgen Inc. for the previous quarter, Wall Street now forecasts -11.92% negative EPS growth.

Since November 29, 2018, it had 0 buys, and 2 insider sales for $4.27 million activity. Patton Cynthia M sold $360,520 worth of stock or 1,777 shares.

Among 27 analysts covering Amgen Inc. (NASDAQ:AMGN), 11 have Buy rating, 0 Sell and 16 Hold. Therefore 41% are positive. Amgen Inc. had 101 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was maintained by BMO Capital Markets on Friday, February 2 with “Market Perform”. On Friday, February 5 the stock rating was initiated by Leerink Swann with “Market Perform”. The rating was maintained by UBS with “Buy” on Thursday, October 29. The rating was maintained by Citigroup with “Neutral” on Friday, July 29. Jefferies maintained Amgen Inc. (NASDAQ:AMGN) rating on Sunday, August 27. Jefferies has “Buy” rating and $200.0 target. Oppenheimer maintained the stock with “Buy” rating in Monday, June 26 report. On Wednesday, July 26 the stock rating was maintained by UBS with “Neutral”. Barclays Capital maintained the shares of AMGN in report on Thursday, April 5 with “Equal-Weight” rating. On Tuesday, September 1 the stock rating was initiated by Raymond James with “Market Perform”. Argus Research maintained the shares of AMGN in report on Monday, February 8 with “Buy” rating.

Investors sentiment decreased to 0.87 in 2018 Q3. Its down 0.12, from 0.99 in 2018Q2. It is negative, as 49 investors sold AMGN shares while 550 reduced holdings. 130 funds opened positions while 393 raised stakes. 470.42 million shares or 2.68% less from 483.36 million shares in 2018Q2 were reported. Signature Fin Mngmt holds 0.31% of its portfolio in Amgen Inc. (NASDAQ:AMGN) for 8,530 shares. Hanson Mcclain holds 1,912 shares or 0.02% of its portfolio. Credit Suisse Ag accumulated 1.33 million shares. Mckinley Capital Limited Liability Company Delaware invested 0.03% of its portfolio in Amgen Inc. (NASDAQ:AMGN). Sns Financial Limited holds 8,577 shares or 0.43% of its portfolio. The Ohio-based Boyd Watterson Asset Mngmt Oh has invested 0.43% in Amgen Inc. (NASDAQ:AMGN). Guggenheim Capital Limited holds 0.48% in Amgen Inc. (NASDAQ:AMGN) or 353,273 shares. Endurance Wealth Mgmt reported 30,926 shares. Ifrah Fin Svcs reported 0.17% stake. Raymond James Services Advisors Inc holds 232,841 shares or 0.22% of its portfolio. 30,408 were reported by Eagle Asset Mgmt. Tuttle Tactical Mngmt has 11,100 shares. Ibm Retirement Fund holds 0.56% of its portfolio in Amgen Inc. (NASDAQ:AMGN) for 11,734 shares. Douglass Winthrop Advsrs Limited Com invested in 2.45% or 267,405 shares. Mraz Amerine And Assocs accumulated 0.37% or 5,996 shares.

Palladium Partners Llc, which manages about $1.69B and $1.47B US Long portfolio, upped its stake in Pepsico Inc Com (NYSE:PEP) by 3,465 shares to 134,235 shares, valued at $15.01 million in 2018Q3, according to the filing. It also increased its holding in General Dynamics Corp Com (NYSE:GD) by 1,623 shares in the quarter, for a total of 53,155 shares, and has risen its stake in Amazon Com Inc Com (NASDAQ:AMZN).

Amgen Inc. (NASDAQ:AMGN) Institutional Positions Chart